Virios Therapeutics, Inc. (NASDAQ:VIRI - Get Free Report) shares were down 1.5% during trading on Friday . The stock traded as low as $4.40 and last traded at $4.56. Approximately 91,031 shares were traded during mid-day trading, a decline of 91% from the average daily volume of 1,049,645 shares. The stock had previously closed at $4.63.
Virios Therapeutics Stock Performance
The firm has a fifty day moving average price of $5.32 and a 200 day moving average price of $4.93. The firm has a market capitalization of $93.40 million, a price-to-earnings ratio of -17.96 and a beta of 1.58.
Virios Therapeutics Company Profile
(
Get Free Report)
Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.
Featured Stories
Before you consider Virios Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Virios Therapeutics wasn't on the list.
While Virios Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
